HomeCompareSMGBY vs PFE

SMGBY vs PFE: Dividend Comparison 2026

SMGBY yields 32.58% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SMGBY wins by $103.8K in total portfolio value
10 years
SMGBY
SMGBY
● Live price
32.58%
Share price
$16.97
Annual div
$5.53
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$153.4K
Annual income
$21,793.51
Full SMGBY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SMGBY vs PFE

📍 SMGBY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSMGBYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SMGBY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SMGBY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SMGBY
Annual income on $10K today (after 15% tax)
$2,768.90/yr
After 10yr DRIP, annual income (after tax)
$18,524.48/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $3,795.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SMGBY + PFE for your $10,000?

SMGBY: 50%PFE: 50%
100% PFE50/50100% SMGBY
Portfolio after 10yr
$101.5K
Annual income
$24,026.11/yr
Blended yield
23.68%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SMGBY
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SMGBY buys
0
PFE buys
0
No recent congressional trades found for SMGBY or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSMGBYPFE
Forward yield32.58%6.13%
Annual dividend / share$5.53$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$153.4K$49.6K
Annual income after 10y$21,793.51$26,258.71
Total dividends collected$107.9K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SMGBY vs PFE ($10,000, DRIP)

YearSMGBY PortfolioSMGBY Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$13,958$3,257.53$9,153$693.39+$4.8KSMGBY
2$19,184$4,249.26$8,593$849.25+$10.6KSMGBY
3$25,985$5,458.28$8,336$1,066.78+$17.6KSMGBY
4$34,714$6,909.70$8,437$1,384.80+$26.3KSMGBY
5$45,770$8,626.87$9,013$1,875.40+$36.8KSMGBY
6$59,605$10,630.52$10,306$2,680.72+$49.3KSMGBY
7$76,715$12,938.01$12,820$4,101.38+$63.9KSMGBY
8$97,648$15,562.65$17,673$6,826.70+$80.0KSMGBY
9$122,996$18,513.19$27,543$12,591.86+$95.5KSMGBY
10$153,400$21,793.51$49,560$26,258.71+$103.8KSMGBY

SMGBY vs PFE: Complete Analysis 2026

SMGBYStock

San Miguel Corporation engages in food and beverage, packaging, energy, fuel and oil, infrastructure, cement, and banking businesses worldwide. Its Food and Beverage segment is involved in feeds production; poultry and livestock farming; processing and selling poultry and meat products and refrigerated processed and canned meat products; milling, producing, and marketing of flour, flour mixes, bakery ingredients, butter, margarine, cheese, milk, ice cream, jelly-based snacks and desserts, oils, salad aids, biscuits, and condiments; importing and marketing of coffee and coffee-related products; and grain terminal handling. This segment also produces, markets, and sells fermented, malt-based, and non-alcoholic beverages; and hard liquor in the form of gin, Chinese wine, brandy, rum, and vodka. Its Packaging segment produces and markets packaging products, such as glass containers and molds, polyethylene terephthalate (PET) bottles and preforms, PET recycling, plastic and metal closures, corrugated cartons, woven polypropylene, kraft sacks and paperboards, pallets, flexible packaging, aluminum cans, woven products, industrial laminates, and radiant barriers; and plastic crates, floorings, films, trays, pails, and tubs. This segment also engages in the crate and plastic pallet leasing, PET bottle filling graphics design, packaging research and testing, packaging development and consultation, and contract packaging and trading activities. Its Energy segment generates, sells, retails, and distributes power. Its Fuel and Oil segment refines and markets petroleum products. Its Infrastructure segment constructs and develops infrastructure projects, such as toll roads, airports, railways, and bulk water. The company also develops, manages, and sells real estate properties; and manufactures and sells cement. The company was founded in 1890 and is headquartered in Mandaluyong City, the Philippines. San Miguel Corporation is a subsidiary of Top Frontier Investment Holdings, Inc.

Full SMGBY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SMGBY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SMGBY vs SCHDSMGBY vs JEPISMGBY vs OSMGBY vs KOSMGBY vs MAINSMGBY vs JNJSMGBY vs MRKSMGBY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.